Skip to main content
Top
Published in: Journal of General Internal Medicine 2/2013

01-02-2013 | Original Research

Association of Body Mass Index, Diabetes, Hypertension, and Blood Pressure Levels with Risk of Permanent Atrial Fibrillation

Authors: Evan L. Thacker, PhD, Barbara McKnight, PhD, Bruce M. Psaty, MD, PhD, W. T. Longstreth Jr., MD, MPH, Sascha Dublin, MD, PhD, Paul N. Jensen, MPH, Katherine M. Newton, PhD, Nicholas L. Smith, PhD, David S. Siscovick, MD, Susan R. Heckbert, MD, PhD

Published in: Journal of General Internal Medicine | Issue 2/2013

Login to get access

ABSTRACT

BACKGROUND

After an initial episode of atrial fibrillation (AF), AF may recur and become permanent. AF progression is associated with higher morbidity and mortality. Understanding the risk factors for permanent AF could help identify people who would benefit most from interventions.

OBJECTIVE

To determine whether body mass index (BMI), diabetes, hypertension, and blood pressure levels are associated with permanent AF among people whose initial AF episode terminated.

DESIGN

Population-based inception cohort study.

PARTICIPANTS

Enrollees in Group Health, an integrated health care system, aged 30–84 with newly diagnosed AF in 2001–2004, whose initial AF terminated within 6 months and who had at least 6 months of subsequent follow-up (N = 1,385).

MAIN MEASURES

Clinical characteristics were determined from medical records. Permanent AF was determined from medical records and ECG and administrative databases. Permanent AF was defined as AF present on two separate occasions 6–36 months apart, without any documented sinus rhythm between the two occasions. Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs).

KEY RESULTS

Five-year cumulative incidence of permanent AF was 24 %. Compared with normal BMI (18.5–24.9 kg/m2), BMI levels of 25.0–29.9 (overweight), 30.0–34.9 (obese 1), 35.0–39.9 (obese 2), and ≥ 40.0 kg/m2 (obese 3) were associated with HRs of permanent AF of 1.26 (95 % CI: 0.92, 1.72); 1.35 (0.96, 1.91); 1.50 (0.97, 2.33); and 1.79 (1.13, 2.84), adjusted for age, sex, diabetes, hypertension, blood pressure, coronary heart disease, valvular heart disease, heart failure, and prior stroke. Diabetes, hypertension, and blood pressure were not associated with permanent AF.

CONCLUSIONS

For people whose initial AF episode terminates, benefits of having lower BMI may include a lower risk of permanent AF. Risk of permanent AF was similar for people with and without diabetes or hypertension and across blood pressure levels.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257–354.PubMedCrossRef Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257–354.PubMedCrossRef
2.
go back to reference Kerr CR, Humphries KH, Talajic M, et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J. 2005;149:489–96.PubMedCrossRef Kerr CR, Humphries KH, Talajic M, et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J. 2005;149:489–96.PubMedCrossRef
3.
go back to reference de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation: clinical correlates and prognosis. J Am Coll Cardiol. 2010;55:725–31.PubMedCrossRef de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation: clinical correlates and prognosis. J Am Coll Cardiol. 2010;55:725–31.PubMedCrossRef
4.
go back to reference Steg PG, Alam S, Chaing CE, et al. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart. 2012;98:195–201.PubMedCrossRef Steg PG, Alam S, Chaing CE, et al. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart. 2012;98:195–201.PubMedCrossRef
5.
go back to reference Patton KK, Page RL. New-onset paroxysmal atrial fibrillation: is permanence inevitable? Am Heart J. 2005;149:388–90.PubMedCrossRef Patton KK, Page RL. New-onset paroxysmal atrial fibrillation: is permanence inevitable? Am Heart J. 2005;149:388–90.PubMedCrossRef
6.
go back to reference Dublin S, French B, Glazer NL, et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med. 2006;166:2322–8.PubMedCrossRef Dublin S, French B, Glazer NL, et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med. 2006;166:2322–8.PubMedCrossRef
7.
go back to reference Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med. 2010;25:853–8.PubMedCrossRef Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med. 2010;25:853–8.PubMedCrossRef
8.
go back to reference Thomas MC, Dublin S, Kaplan RC, et al. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens. 2008;21:1111–6.PubMedCrossRef Thomas MC, Dublin S, Kaplan RC, et al. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens. 2008;21:1111–6.PubMedCrossRef
9.
go back to reference Tsang TS, Barnes ME, Miyasaka Y, et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J. 2008;29:2227–33.PubMedCrossRef Tsang TS, Barnes ME, Miyasaka Y, et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J. 2008;29:2227–33.PubMedCrossRef
10.
go back to reference Heckbert SR, Wiggins KL, Glazer NL, et al. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. Am J Hypertens. 2009;22:538–44.PubMedCrossRef Heckbert SR, Wiggins KL, Glazer NL, et al. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. Am J Hypertens. 2009;22:538–44.PubMedCrossRef
11.
go back to reference Glazer NL, Dublin S, Smith NL, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007;167:246–52.PubMedCrossRef Glazer NL, Dublin S, Smith NL, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007;167:246–52.PubMedCrossRef
12.
go back to reference Arterburn D, Ichikawa L, Ludman EJ, et al. Validity of clinical body weight measures as substitutes for missing data in a randomized trial. Obes Res Clin Pract. 2008;2:277–81.PubMedCrossRef Arterburn D, Ichikawa L, Ludman EJ, et al. Validity of clinical body weight measures as substitutes for missing data in a randomized trial. Obes Res Clin Pract. 2008;2:277–81.PubMedCrossRef
13.
go back to reference Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.PubMedCrossRef Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.PubMedCrossRef
14.
go back to reference Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata J. 2004;4:103–12. Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata J. 2004;4:103–12.
15.
go back to reference Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34:541–54.PubMedCrossRef Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34:541–54.PubMedCrossRef
16.
go back to reference Zhang X, Zhang S, Li Y, et al. Association of obesity and atrial fibrillation among middle-aged and elderly Chinese. Int J Obes. 2009;33:1318–25.CrossRef Zhang X, Zhang S, Li Y, et al. Association of obesity and atrial fibrillation among middle-aged and elderly Chinese. Int J Obes. 2009;33:1318–25.CrossRef
17.
go back to reference Guglin M, Maradia K, Chen R, Curtis AB. Relation of obesity to recurrence rate and burden of atrial fibrillation. Am J Cardiol. 2011;107:579–82.PubMedCrossRef Guglin M, Maradia K, Chen R, Curtis AB. Relation of obesity to recurrence rate and burden of atrial fibrillation. Am J Cardiol. 2011;107:579–82.PubMedCrossRef
18.
go back to reference Kistler PM, Sanders P, Morton JB, Vohra JK, Kalman JM, Sparks PB. Effect of body mass index on defibrillation thresholds for internal cardioversion in patients with atrial fibrillation. Am J Cardiol. 2004;94:370–2.PubMedCrossRef Kistler PM, Sanders P, Morton JB, Vohra JK, Kalman JM, Sparks PB. Effect of body mass index on defibrillation thresholds for internal cardioversion in patients with atrial fibrillation. Am J Cardiol. 2004;94:370–2.PubMedCrossRef
19.
go back to reference Freynhofer MK, Jarai R, Hochtl T, et al. Predictive value of plasma Nt-proBNP and body mass index for recurrence of atrial fibrillation after cardioversion. Int J Cardiol. 2011;149:257–9.PubMedCrossRef Freynhofer MK, Jarai R, Hochtl T, et al. Predictive value of plasma Nt-proBNP and body mass index for recurrence of atrial fibrillation after cardioversion. Int J Cardiol. 2011;149:257–9.PubMedCrossRef
20.
go back to reference Cha Y-M, Friedman PA, Asirvatham SJ, et al. Catheter ablation for atrial fibrillation in patients with obesity. Circulation. 2008;117:2583–90.PubMedCrossRef Cha Y-M, Friedman PA, Asirvatham SJ, et al. Catheter ablation for atrial fibrillation in patients with obesity. Circulation. 2008;117:2583–90.PubMedCrossRef
21.
go back to reference Chilukuri K, Dalal D, Gadrey S, et al. A prospective study evaluating the role of obesity and obstructive sleep apnea for outcomes after catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2010;21:521–5.PubMedCrossRef Chilukuri K, Dalal D, Gadrey S, et al. A prospective study evaluating the role of obesity and obstructive sleep apnea for outcomes after catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2010;21:521–5.PubMedCrossRef
22.
go back to reference Jongnarangsin K, Chugh A, Good E, et al. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19:668–72.PubMedCrossRef Jongnarangsin K, Chugh A, Good E, et al. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19:668–72.PubMedCrossRef
23.
go back to reference Needleman M, Calkins H. The role of obesity and sleep apnea in atrial fibrillation. Curr Opin Cardiol. 2011;26:40–5.PubMedCrossRef Needleman M, Calkins H. The role of obesity and sleep apnea in atrial fibrillation. Curr Opin Cardiol. 2011;26:40–5.PubMedCrossRef
24.
go back to reference Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity—results of a meta-analysis. Am Heart J. 2008;155:310–5.PubMedCrossRef Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity—results of a meta-analysis. Am Heart J. 2008;155:310–5.PubMedCrossRef
25.
go back to reference Badheka AO, Rathod A, Kizilbash MA, et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med. 2010;123:646–51.PubMedCrossRef Badheka AO, Rathod A, Kizilbash MA, et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med. 2010;123:646–51.PubMedCrossRef
26.
go back to reference Ardestani A, Hoffman HJ, Cooper HA. Obesity and outcomes among patients with established atrial fibrillation. Am J Cardiol. 2010;106:369–73.PubMedCrossRef Ardestani A, Hoffman HJ, Cooper HA. Obesity and outcomes among patients with established atrial fibrillation. Am J Cardiol. 2010;106:369–73.PubMedCrossRef
Metadata
Title
Association of Body Mass Index, Diabetes, Hypertension, and Blood Pressure Levels with Risk of Permanent Atrial Fibrillation
Authors
Evan L. Thacker, PhD
Barbara McKnight, PhD
Bruce M. Psaty, MD, PhD
W. T. Longstreth Jr., MD, MPH
Sascha Dublin, MD, PhD
Paul N. Jensen, MPH
Katherine M. Newton, PhD
Nicholas L. Smith, PhD
David S. Siscovick, MD
Susan R. Heckbert, MD, PhD
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 2/2013
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-012-2220-4

Other articles of this Issue 2/2013

Journal of General Internal Medicine 2/2013 Go to the issue

Clinical Practice: Exercises in Clinical Reasoning

More than Skin Deep

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine